Corvus Pharmaceuticals, Inc. jumps 165% on Phase 1 soquelitinib atopic dermatitis data; learn key efficacy, funding, and ...
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to ...
The future of health innovation will not be defined by replacing existing medical models, but by strengthening biological regulation earlier—before pathology becomes visible.
Iran's Jamming of Starlink uses military-grade electronic warfare (EW) tools, likely imported from China and Russia deployed via mobile platforms like trucks ...
The blueprint was developed through working groups and workshops hosted by the UK Textiles Pact during 2025, building on a cross-industry position statement released in summer 2025 by WRAP, the ...
Trial Results Support Transition into Late-Stage Development with Program Expected to be Phase 2b/3-ready in H2 2026 BERLIN, GERMANY, January 29, 2026 – OMEICOS, a clinical-stage biopharmaceutical ...
ROHM extended the library of EROM-format models for its shunt resistors targeting automotive and industrial systems.
Krystal Biotech is upgraded to Strong Buy as Vyjuvek sales surge and catalysts build. Click here to know more.
Interim analyses on track for the first and second half of 2026SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage ...
When a biotech company announces positive Phase 3 trial results or receives FDA approval, the market reaction is often immediate and substantial. This is not just speculation. These milestones ...
Detailed price information for Janux Therapeutics Inc (JANX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results